Long term safety of infliximab;Traitement de maladies inflammatoires: Sécurité d'emploi à long terme de l'infliximab

Presse Medicale

Volumn 30, Issue 12, 2001, Pages 610-613

  Schaible, T F ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; INFLIXIMAB; PLACEBO;

ANTIBODY TITER; CHILL; CLINICAL TRIAL; CROHN DISEASE; DRUG SAFETY; FEVER; HEADACHE; HUMAN; INCIDENCE; LUPUS VULGARIS; MORTALITY; REVIEW; RHEUMATOID ARTHRITIS; THORAX PAIN; URTICARIA;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CONTROLLED CLINICAL TRIALS; CROHN DISEASE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 0035978073     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor for Crohn's disease cA2 Study group
2. Infliximab treatment of fistulas in patients with Crohn's disease
3. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
4. Treatment of Crohn's disease anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
5. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α
6. Randomized double-blind comparison of chimeric monoclonal antibodies to tumor necrosis factor-α (cA2) versus placebo in rheumatoid arthritis
7. Therapeutic efficacity of multiple intravenous infusions and anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
8. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rhumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial
9. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
10. Construction and initial characterization of a mouse human chimeric anti-TNF antibody
11. Chimeric anti TNF-alpha monoclonal antibody cA2 bind recombinant transmembrane TNF-alpha and activates immune effector functions
12. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF in vivo
13. Administration of anti-tumor necrosis factor (TNF) monoclonical antibody (MAB) induces lupus-like autoimmunity in the parent-into f1 (P-F1) model of acute graft versus host disease (GVHD)
14. Tumor necrosis factor-alpha in murine autoimmune «lupus» nephritis